Right time to take profit off the table in pharma ; defence a structural buy : Rajiv (...)
Rajiv Batra addresses global investors' concerns about India's growth and policy, emphasizing the need for double-digit earnings and nominal GDP growth to reignite foreign investor interest. He suggests profit-taking in pharma due to US generic concerns and underwhelming earnings. Batra remains (...)
Site référencé: The Economic Times
The Economic Times
Top 10 mutual funds for SIP to invest with a horizon of 5 years
23/08/2025
4 stocks from Ashish Kacholia's portfolio surged 50-75% in FY26
23/08/2025
Explained : Why understanding riskometer of mutual fund is important
23/08/2025
Fitch affirms US credit at 'AA+', rising debt a ratings constraint
23/08/2025
Coal India, REC among top 10 largecap stocks with highest dividend yield in 1 year
23/08/2025
Fund Manager Talk | Ajay Khandelwal on India ⓐ 2047 : Markets, shifts, and opportunities ahead
23/08/2025
